GlassScriptPhysician profile
John R Amrien
NPI 1497757173
$4,122.16
in general payments reported to CMS, 2019-2025
34 companies · $995 in 2025
The $995 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,537 · 2020: $307 · 2021: $122 · 2022: $55.14 · 2023: $575 · 2024: $531 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $661.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $482.64 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $377.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $308.44 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $223.39 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $221.72 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $220.29 | 2019-2024 | Livalo, Seglentis |
| Novo Nordisk INC | $213.32 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $207.21 | 2019-2021 | |
| Philips North America LLC | $188.24 | 2019-2020 | |
| Antares Pharma, INC. | $109.09 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Lundbeck LLC | $96.87 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.66 | 2019-2025 | Xifaxan |
| Eisai INC. | $78.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.97 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $66.31 | 2023-2025 | Gralise, Loreev Xr |
| Astellas Pharma US INC | $59.00 | 2019-2024 | Veozah |
| Amgen INC. | $54.29 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $44.79 | 2022-2025 | |
| Amarin Pharma, INC. | $43.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.58 | 2019 | |
| Halozyme INC | $37.52 | 2023 | |
| Sanofi-Aventis U.S. LLC | $35.62 | 2019-2025 | |
| Exact Sciences Corporation | $30.14 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $25.20 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $20.94 | 2025 | Trelstar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.12 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2023 | |
| Axsome Therapeutics, INC. | $16.80 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.13 | 2024 | Quviviq |
| Bausch Health US, LLC | $15.42 | 2025 | Aplenzin, Wellbutrin |
| Tolmar, INC. | $14.87 | 2023 | |
| Hikma Pharmaceuticals USA | $12.99 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Amrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.